Skip to content
ClinCalc Pro
Menu
Antiprotozoal (PCP, leishmaniasis, trypanosomiasis) Pregnancy: There is none or very limited experience with the use of pentamidine in pregnant women; animal studies have shown reproductive toxicity, and a miscarriage was reported after inhalation of pentamidine for prophylaxis in the first trimester. Should not be used during pregnancy unless therapy is required due to the woman's clinical condition. Breast-feeding: it is not known if pentamidine/metabolites are excreted in breast milk — breastfeeding should be discontinued during pentamidine therapy.

Pentamidine isetionate

Brand names: Pentacarinat

Pentamidine isetionate is an antiprotozoal and antifungal agent used for Pneumocystis jirovecii pneumonia (treatment and prophylaxis), leishmaniasis and early-stage African trypanosomiasis, generally as a second-line option.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Pneumocystis jirovecii pneumonia, treatment: 4 mg pentamidine isetionate per kg body weight once daily, preferably administered by slow intravenous infusion over 60 minutes.
Route: Slow intravenous infusion over 60 minutes (the SPC also covers intramuscular injection and nebulised inhalation, depending on the indication)
Frequency: Once daily
Max: The total duration of therapy should not exceed 21 days (a therapy duration of 14 days is generally sufficient; prolonging may be necessary in some severe cases)
The SPC states these dosage recommendations apply to adults, adolescents, children and infants. OTHER REGIMENS FROM THE SAME SPC — Pneumocystis jirovecii pneumonia, PROPHYLAXIS: inhalation is recommended; the adult dosage for inhalation is 150 mg pentamidine isetionate every two weeks, or one dose of 300 mg once a month. Visceral leishmaniasis: 3-4 mg pentamidine isetionate per kg body weight, most conveniently administered by intramuscular injection every other day; the number of applications should not exceed 10, though a second treatment cycle is possible if necessary. Cutaneous leishmaniasis: 3-4 mg per kg body weight every other day for 3-4 doses, by intramuscular injection or intravenous infusion. Human African trypanosomiasis: 4 mg per kg body weight once a day or every other day, injected intramuscularly or infused intravenously, up to a total of 7-10 applications. ADMINISTRATION SAFETY: there may be a sudden and severe fall in blood pressure even after an injection, so the patient should be reclining; check blood pressure supine before administration and monitor continuously during and after the infusion/injection and regularly until the end of therapy. Regular monitoring required of blood urea nitrogen and serum creatinine daily, full blood count each day of therapy, fasting blood sugar each therapy day and at intervals after therapy ends, and liver function tests. Pentamidine isetionate may prolong the QT interval — monitor QTc in patients with known or suspected cardiac disease or on concomitant QT-prolonging medicines; take special care if QTc exceeds 500 ms and consider alternative therapy if QTc exceeds 550 ms. DOSAGE EQUIVALENCE: 4 mg of pentamidine isetionate contains 2.3 mg pentamidine base; 1 mg of pentamidine base is equivalent to 1.74 mg pentamidine isetionate. Displacement value: 300 mg pentamidine isetionate displaces approximately 0.15 ml of water. INHALATION: give a bronchodilator by metered dose inhaler 5-10 minutes before inhalation; use a nebuliser producing 1-5 micron particles in a vacated, well-ventilated room with staff in protective clothing; reconstitute in a fume cupboard. Hepatic impairment: no specific dosage recommendations. Elderly: no specific dosage recommendations. NOTE: the fetched SPC sections 4.4 and 4.8 were truncated at the source-fetch limit and section 4.5 (interactions) was not retrieved in full — the lists below are incomplete.

Paediatric dose

Dose: 4 mg/kg
Route: Slow intravenous infusion over 60 minutes
Frequency: Once daily
Max: Total duration of therapy should not exceed 21 days
Figure shown is the SPC treatment dose for Pneumocystis jirovecii pneumonia (4 mg pentamidine isetionate per kg body weight once daily by slow IV infusion over 60 minutes; 14 days is generally sufficient). The SPC applies the adult figures to children: section 4.2 opens 'The following dosage recommendations apply to adults, adolescents, children and infants' and under Paediatric population states 'For infants, children and adolescents, the dosage recommendations given above apply.' No separate paediatric figure is given. Other indications in the same SPC use 3-4 mg/kg (leishmaniasis) or 4 mg/kg (trypanosomiasis) — see adultDose.notes. Verify against a children's formulary before prescribing.

Dose adjustments

Renal

In severely impaired renal function (creatinine clearance <10 ml/min) a dose adjustment is required: for life-threatening Pneumocystis jirovecii pneumonia, 4 mg/kg once daily for 7-10 days, thereafter every 2 days to a total of at least 14 doses; in less severe Pneumocystis jirovecii pneumonia, 4 mg/kg every 2 days; for trypanosomiasis and leishmaniasis the dosing interval should not be less than 48 hours. In mild renal impairment, at least 36 hours should have elapsed between doses.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

Figure shown is the SPC treatment dose for Pneumocystis jirovecii pneumonia (4 mg pentamidine isetionate per kg body weight once daily by slow IV infusion over 60 minutes; 14 days is generally sufficient). The SPC applies the adult figures to children: section 4.2 opens 'The following dosage recommendations apply to adults, adolescents, children and infants' and under Paediatric population states 'For infants, children and adolescents, the dosage recommendations given above apply.' No separate paediatric figure is given. Other indications in the same SPC use 3-4 mg/kg (leishmaniasis) or 4 mg/kg (trypanosomiasis) — see adultDose.notes. Verify against a children's formulary before prescribing.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance

Side effects

  • Parenteral, very common: azotaemia; acute renal failure (potentially life-threatening); macroscopic haematuria
  • Parenteral, very common: local reactions ranging from swelling, inflammation and pain to induration, abscess formation and muscle necrosis
  • Parenteral, common: hypoglycaemia, hyperglycaemia, diabetes mellitus (also persistent), hypomagnesaemia, hyperkalaemia and hypocalcaemia (potentially life-threatening)
  • Parenteral, common: hypertension or hypotension (potentially life-threatening), circulatory collapse, flushing; syncope and dizziness
  • Parenteral, common: anaemia, leukopenia and thrombocytopenia (potentially life-threatening)
  • Parenteral, rare: QT interval prolongation and arrhythmia (potentially life-threatening); pancreatitis (potentially life-threatening); Torsades de Pointes and bradycardia (frequency not known)
  • Inhalation, common: cough, dyspnoea, wheezing, bronchospasm (especially in smokers or asthmatics), dysgeusia, nausea

Interactions

  • QT-prolonging medicinal products — use pentamidine isetionate with caution during concomitant administration, and in patients at increased risk of cardiac arrhythmias, prolonged QT syndrome, cardiac disease, known ventricular arrhythmias, bradycardia (<50 bpm), or untreated hypokalaemia and/or hypomagnesaemia (stated in SPC section 4.4 cross-referencing section 4.5; section 4.5 itself was NOT retrieved in this fetch, so this list is incomplete)

Clinical monograph

How it works

It interferes with protozoal and fungal nucleic acid and folate metabolism and disrupts mitochondrial function, although its precise mode of action is not fully defined.

Prescribing in practice

  • Parenteral use can cause severe hypotension, dysglycaemia (both hypoglycaemia and hyperglycaemia), QT prolongation and acute renal impairment, so administration with the patient lying down and close cardiovascular and metabolic monitoring is essential.
  • Nebulised administration is used for Pneumocystis prophylaxis and may provoke bronchospasm, which can be reduced by prior bronchodilator use.
  • Doses should be adjusted in renal impairment in line with the SPC and specialist advice.

Monitoring

Monitor blood pressure, blood glucose, renal and hepatic function, electrolytes including potassium and magnesium, full blood count and ECG during therapy.

Counselling the patient

  • Stay lying down during and after an infusion because of the risk of a sudden fall in blood pressure.
  • Report dizziness, palpitations, or symptoms of low or high blood sugar.
  • With the inhaled form, tell the team if you develop wheeze or chest tightness.

Evidence & guidelines

Pentamidine is an established alternative to co-trimoxazole for Pneumocystis jirovecii pneumonia where the first-line agent is unsuitable.

Reference: BHIVA OI guidelines; UKHSA imported infections guidance; WHO leishmaniasis; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.